Genocea Biosciences, Inc. (NASDAQ:GNCA) was downgraded by Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued on Monday, The Fly reports.

Several other research analysts have also recently weighed in on the company. Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Monday, July 24th. Zacks Investment Research cut Genocea Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Cowen and Company reiterated an “outperform” rating and set a $40.00 price target on shares of Genocea Biosciences in a research report on Tuesday, July 25th. ValuEngine cut Genocea Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $18.00 price target (up from $17.00) on shares of Genocea Biosciences in a research report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $16.52.

Genocea Biosciences (NASDAQ:GNCA) traded up 0.38% during midday trading on Monday, hitting $5.31. 320,728 shares of the stock traded hands. Genocea Biosciences has a 12 month low of $3.28 and a 12 month high of $7.29. The company has a 50-day moving average of $4.75 and a 200-day moving average of $5.55. The stock’s market cap is $151.99 million.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.08). On average, equities research analysts anticipate that Genocea Biosciences will post ($1.98) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Stifel Nicolaus Lowers Genocea Biosciences, Inc. (GNCA) to Hold” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/25/stifel-nicolaus-lowers-genocea-biosciences-inc-gnca-to-hold.html.

In related news, CFO Jonathan Poole sold 45,000 shares of Genocea Biosciences stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the transaction, the chief financial officer now directly owns 84,247 shares in the company, valued at $505,482. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.70% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in shares of Genocea Biosciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 136,990 shares of the biotechnology company’s stock valued at $1,060,000 after buying an additional 1,743 shares in the last quarter. Alyeska Investment Group L.P. increased its position in shares of Genocea Biosciences by 0.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 225,569 shares of the biotechnology company’s stock valued at $929,000 after buying an additional 1,798 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Genocea Biosciences by 11.5% in the second quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 2,300 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Genocea Biosciences in the first quarter valued at approximately $103,000. Finally, FMR LLC increased its position in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock valued at $26,033,000 after buying an additional 18,574 shares in the last quarter. Institutional investors own 59.25% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

The Fly

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.